Rxsight, Inc. ( (RXST) ) has released its Q3 earnings. Here is a breakdown of the information Rxsight, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
RxSight, Inc. is an ophthalmic medical device company specializing in post-cataract surgery vision solutions, known for its innovative Light Adjustable Lens technology. In its third quarter of 2025 financial report, RxSight revealed a 14% decline in revenue compared to the previous year, with total revenue reaching $30.3 million. Despite the revenue drop, the company saw a 6% increase in Light Adjustable Lens procedure volume and a notable improvement in gross margin to 80%, up from 71% in the same quarter of 2024. The company also reported a net loss of $9.8 million, an increase from the $6.3 million loss in the third quarter of 2024, attributed to ongoing investments in sales and R&D. Strategically, RxSight has realigned its U.S. commercial operations and launched new engagement programs to boost procedure growth and deepen customer relationships. Looking forward, RxSight has narrowed its full-year revenue guidance and raised its gross margin expectations, indicating a cautious yet optimistic outlook for the remainder of 2025.